1. Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU). Issue 1 (1st January 2023) Authors: Rosenberg, Jonathan E.; Park, Se Hoon; Kozlov, Vadim; Dao, Tu V.; Castellano, Daniel; Li, Jian-Ri; Mukherjee, Som D.; Howells, Kathryn; Dry, Hannah; Lanasa, Mark C.; Stewart, Ross; Bajorin, Dean F. Journal: Journal of clinical oncology Issue: Volume 41:Issue 1(2023) Page Start: 43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression. Issue 3 (14th October 2022) Authors: Sternberg, Cora N.; Petrylak, Daniel P.; Bellmunt, Joaquim; Nishiyama, Hiroyuki; Necchi, Andrea; Gurney, Howard; Lee, Jae-Lyun; van der Heijden, Michiel S.; Rosenbaum, Eli; Penel, Nicolas; Pang, See-Tong; Li, Jian-Ri; García del Muro, Xavier; Joly, Florence; Pápai, Zsuzsanna; Bao, Weichao; Elling... Journal: Journal of clinical oncology Issue: Volume 41:Issue 3(2023) Page Start: 629 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗